Recent

% | $
Quotes you view appear here for quick access.

ViroPharma Incorporated Message Board

lennox64 13 posts  |  Last Activity: Mar 25, 2015 6:07 PM Member since: Apr 16, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • lennox64 by lennox64 Mar 25, 2015 6:07 PM Flag

    Dr Ogurts ref to gene therapy not working well in larger animals is referencing AAV2 as a delivery mechanism. Just google the doctors name. Celladon uses AAV1. Which per *******http://www.ncbi.nlm.nih.gov/pubmed/16409124******* is a better delivery mechanism. The Streets article does admit that in the high dose group the gene was still present in 3 of the 4 patients available.

    Sentiment: Strong Buy

  • Reply to

    Guaranteed Failure of Mydicar

    by the_real_biotrader Mar 23, 2015 5:59 PM
    lennox64 lennox64 Mar 23, 2015 7:37 PM Flag

    Oh so you're like a saint in the fact that you want to save others from themselves. Thank you. =) I'm sure heaven will greet you with open arms.

    Sentiment: Strong Buy

  • Reply to

    Guaranteed Failure of Mydicar

    by the_real_biotrader Mar 23, 2015 5:59 PM
    lennox64 lennox64 Mar 23, 2015 7:16 PM Flag

    also from your posting history it looks like you work hard at calling failures for other stocks as well. I assume you have no interest in those either?

    Sentiment: Strong Buy

  • Reply to

    Guaranteed Failure of Mydicar

    by the_real_biotrader Mar 23, 2015 5:59 PM
    lennox64 lennox64 Mar 23, 2015 7:11 PM Flag

    You're working pretty hard for someone with no interest. =) I'm sure you're very honest.

    Sentiment: Strong Buy

  • lennox64 lennox64 Mar 23, 2015 7:03 PM Flag

    you can also google it.

    Sentiment: Strong Buy

  • lennox64 lennox64 Mar 23, 2015 7:03 PM Flag

    on their website

    Sentiment: Strong Buy

  • Reply to

    Guaranteed Failure of Mydicar

    by the_real_biotrader Mar 23, 2015 5:59 PM
    lennox64 lennox64 Mar 23, 2015 7:02 PM Flag

    What makes you think it is inert? Data so far is favoring Mydicar. Anyways don't bet the house!! Haha. We'll see soon. Yes crazy to bet the house, but even more crazy to short as your loss is unlimited if it goes the wrong way.

    Sentiment: Strong Buy

  • Reply to

    Guaranteed Failure of Mydicar

    by the_real_biotrader Mar 23, 2015 5:59 PM
    lennox64 lennox64 Mar 23, 2015 6:55 PM Flag

    Data mining but you left out this from that Credit Suisse Paper and rem threshold is low at 45% they would have to fail big time from the 88% from cupid 1 trial: but yes I agree high risk high reward

    Credit Suisse Paper:
    "These differences generally point to healthier patients in the Mydicar High-Dose cohort relative to the placebo cohort.
    Post-hoc sensitivity analyses though suggest that the clinical impact of
    Mydicar High-Dose could not be fully explained by these differences
     The differences in baseline patient characteristics likely do not completely explain the impact observed with Mydicar High-Dose
    on clinical parameters. Nevertheless, these differences likely impact the observed clinical trends to some degree.
    – The post-hoc sensivitiy analyses were significantly biased in favor of placebo. These sensivity analyses involved exclusion of the “highest
    risk” placebo patients based on the lowest VO2 max, highest creatinine, and very high NT-proBNP.
    – In general, the differences in baseline patient characteristics were narrowed between Mydicar High-Dose and placebo. However, there
    were still some differences in clinical criteria between these 2 patient cohorts.
     The observed clinical impact favoring Mydicar High-Dose over placebo generally remained intact after these post-hoc analyses
    – Mydicar continued to show favorable trends on clinical impact on changes in NYHA class, MLWHFQ, 6-minute walk test, peak VO2, NTproBNP,
    end-systolic volume, and ejection fraction over placebo.
    – The hazard ratios for time-to-recurrent events at 6-months, 9-months, and 12-months for Mydicar High-Dose relative to placebo increased
    slightly to 0.19 (from 0.13), 0.14 (from 0.10), and 0.15 (from 0.12) respectively.
    – The trends for primary endpoints at 6 months remain intact after adjusting for baseline imbalances in VO2 max. Notably, Mydicar High-Dose
    had an adjusted duration of cardiovascular hospitalizations of 1.9 days (vs. 0.5 days for placebo, p=0.199)"

    Sentiment: Strong Buy

  • lennox64 lennox64 Mar 23, 2015 5:35 PM Flag

    Seriously? Come on this is a message board. Risk what you can afford to lose. Whatever allows you to sleep at night.

    Sentiment: Strong Buy

  • lennox64 lennox64 Mar 23, 2015 5:28 PM Flag

    Not sure if you can depend on yahoo message board research. But yeah downside is huge as the company is pretty much Mydicar right now. But upside is much larger in my opinion as this could potentially be a multibillion dollar drug if it works. In the small sample size it had amazing results. Cupid 2 is a much larger trial. I think the odds are pretty good. Cupid 2 is only looking for a threshold of 45% reduction and Cupid 1 had 88% reduction. So the margin for failure is pretty large. So this is why this stock that has a potential multibillion dollar drug is trading so low right now. For some the risk is too great for one event. For others it's not. If the results are good? I would look at stocks like ICPT and PBYI to see how results from one event could propel a stock with a tiny float. IMO this could be trading for hundreds of dollars a share....or $3 haha.

    Sentiment: Strong Buy

  • Reply to

    May 15 puts are trading for $5?!

    by bobwins_o_phile Mar 22, 2015 5:21 PM
    lennox64 lennox64 Mar 23, 2015 3:44 PM Flag

    And you don't think the calls have huge premiums? People are expecting a huge move either up or down.
    They're is a make or break data read out from their Cupid 2 phase 2b trial for Mydicar currently scheduled for end of April.

    Sentiment: Strong Buy

  • Reply to

    Conference call

    by cldx_58 Feb 19, 2015 4:54 PM
    lennox64 lennox64 Feb 23, 2015 9:34 AM Flag

    Boom!!! haha

    Sentiment: Strong Buy

  • Reply to

    Conference call

    by cldx_58 Feb 19, 2015 4:54 PM
    lennox64 lennox64 Feb 20, 2015 11:57 AM Flag

    Well their earnings call is usually in March. So it's a bit earlier this year and they announce it two trading days ahead. Maybe something came up that they had to announce?

    Sentiment: Strong Buy

VPHM
49.96+0.01(+0.02%)Jan 23 4:00 PMEST